Ptc Therapeutics (PTCT) Preferred Stock Liabilities (2012)

Ptc Therapeutics' (PTCT) quarterly Preferred Stock Liabilities came in at $80.8 million in Q4 2012.

Ptc Therapeutics (PTCT) Preferred Stock Liabilities (2012) Analysis & Trends

Ptc Therapeutics' Preferred Stock Liabilities history runs 1 years deep, the most recent figure standing at $80.8 million for Q4 2012.

On a quarterly basis, Preferred Stock Liabilities changed N/A year-over-year to $80.8 million in Q4 2012; TTM through Dec 2012 was $80.8 million, a N/A change from a year earlier, with the FY2012 full-year figure at $80.8 million, down 62.3% from the prior year.
Preferred Stock Liabilities held at $80.8 million in Q4 2012 per PTCT's latest filing.
Across five years, Preferred Stock Liabilities topped out at $80.8 million in Q4 2012 and bottomed at $80.8 million in Q4 2012.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Ptc Therapeutics	6.47 Bn	4.58 Bn	244.52 Mn	-

Download Data

Date	Value
Dec 31, 2012	80.82 Mn